• KOLs
  • T2c Car
  • Kaiyang Ding

Direct Impact

Concepts for which Kaiyang Ding has direct influence:

t2c car
lymphocyte tumor
refractory diffuse
small lymphocytic
multicenter phase
evaluate icp-022
cells lymphoma

External impact

Concepts related to the work of other authors for which Kaiyang Ding has influence:

target surface
underwater ranging
photoacoustic occurring

Prominent publications by Kaiyang Ding

KOL-Index: 8 Complexities of the underwater environment can seriously affect many underwater detection means, especially the influence of light scattering by water. To solve this problem, a three-dimensional (3D) morphology measurement method is proposed based on the photoacoustic effect. In this method, a measurement object is irradiated with pulsed laser light to produce ultrasonic waves via the ...
Known for
Pulsed Laser Light | Three-Dimensional Morphology Measurement Method | Directivity | Ultrasonic Waves
KOL-Index: 2 This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.. This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated ...
Known for
Phase Evaluate | Untreated Chronic | Multicenter Open | Safety Icp-022
KOL-Index: 2 This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of CT103A in subjects with relapsed and refractory MM. Detailed Description Leukapheresis procedure will be performed to manufacture CT103A chimeric antigen receptor (CAR) modified T cells. Bridging therapy is allowed between PBMC collection and lymphodepletion. Lymphodepletion with ...
Known for
Bridging Therapy | Pbmc Collection
KOL-Index: 2 1. To explore the value of combined with liquid biopsy and second-generation sequencing technology detecting cfDNA in DLBCL risk stratification, efficacy assessment, dynamic follow-up, and compare it with current commonly used PET-CT efficacy evaluation, in order to estimate the effect of cfDNA and PET-CT in DLBCL efficacy evaluation; 2. After 4 weeks of treatment with the low-dose ...
Known for
Adjuvant Cells | Test Protocol
KOL-Index: 2 The safety and feasibility of CAR-T cells (CD19.CAR-T) targeted at CD19 in the treatment of relapsed / refractory CD19 positive lymphoma were determined, and the proliferation and survival time of CD19.CAR-T cells in patients were determined. Detailed Description The sponsors of this research also studied CD19.CAR-T cells for the treatment of leukemia and lymphoma, two courses of three ...
Known for
Survival Time | Safety Feasibility | Therapy Relapsed | Determined Proliferation
KOL-Index: 2 An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma. Detailed Description This study is an open, dose escalation/dose regimen finding study to assess the safety and pharmacokinetics of donor-derived CD20-directed ...
Known for
Safety Tolerability | Single Open | Mantle Small | Phase Evaluate
KOL-Index: 2 A Phase I, Multicenter study to evaluate the safety, tolerability, and Efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+T Lymphocyte Tumor Patients. Detailed Description This is an open, dose escalation/dose extension study of LCAR-T2C CAR-T cells administrered to patients with T lymphocyte tumor. The aim of the study is to evaluate the safety, tolerability, and efficacy of ...
Known for
Multicenter Evaluate | Refractory Cd4t | Detailed Open | Cd4 Lymphocyte

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172